title: Virotherapy: cancer gene therapy at last?
abstract: For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated experience from previous clinical studies has finally led the field to its first licensed therapy. Following a pivotal phase III trial, Imlygic (talimogene laherparepvec/T-Vec) received US approval as a treatment for cutaneous and subcutaneous melanoma in October 2015, followed several weeks later by its European authorisation. These represent the first approvals for an oncolytic virotherapy. Imlygic is an advanced-generation herpesvirus-based vector optimised for oncolytic and immunomodulatory activities. Many other oncolytic agents currently remain in development, providing hope that current success will be followed by other diverse vectors that may ultimately come to constitute a new class of clinical anti-cancer agents. In this review, we discuss some of the key oncolytic viral agents developed in the adenovirus and herpesvirus classes, and the prospects for further enhancing their efficacy by combining them with novel immunotherapeutic approaches.
authors.affiliation: Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, G61 1QH, UK.
authors.forename: Alan E
authors.initials: AE
authors.lastname: Bilsland
authors.affiliation: Beatson West of Scotland Cancer Centre, Glasgow, G12 OYN, UK.
authors.forename: Pavlina
authors.initials: P
authors.lastname: Spiliopoulou
authors.affiliation: Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, G61 1QH, UK.
authors.forename: T R Jeffry
authors.initials: TR
authors.lastname: Evans
keywords: Cancer gene therapy; Imlygic; adenovirus; cancer immunotherapy; herpesvirus; oncolytic virus